These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 28233992

  • 1. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
    Herrera A, Muñoz P, Steinbusch HWM, Segura-Aguilar J.
    ACS Chem Neurosci; 2017 Apr 19; 8(4):702-711. PubMed ID: 28233992
    [Abstract] [Full Text] [Related]

  • 2. Protective and toxic roles of dopamine in Parkinson's disease.
    Segura-Aguilar J, Paris I, Muñoz P, Ferrari E, Zecca L, Zucca FA.
    J Neurochem; 2014 Jun 19; 129(6):898-915. PubMed ID: 24548101
    [Abstract] [Full Text] [Related]

  • 3. Neuroprotection against Aminochrome Neurotoxicity: Glutathione Transferase M2-2 and DT-Diaphorase.
    Segura-Aguilar J, Muñoz P, Inzunza J, Varshney M, Nalvarte I, Mannervik B.
    Antioxidants (Basel); 2022 Jan 31; 11(2):. PubMed ID: 35204179
    [Abstract] [Full Text] [Related]

  • 4. Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson's disease.
    Paris I, Cardenas S, Lozano J, Perez-Pastene C, Graumann R, Riveros A, Caviedes P, Segura-Aguilar J.
    Neurotox Res; 2007 Sep 31; 12(2):125-34. PubMed ID: 17967736
    [Abstract] [Full Text] [Related]

  • 5. 5-S-cysteinyl-dopamine, a neurotoxic endogenous metabolite of dopamine: Implications for Parkinson's disease.
    Badillo-Ramírez I, Saniger JM, Rivas-Arancibia S.
    Neurochem Int; 2019 Oct 31; 129():104514. PubMed ID: 31369776
    [Abstract] [Full Text] [Related]

  • 6. Direct intranigral injection of dopaminochrome causes degeneration of dopamine neurons.
    Touchette JC, Breckenridge JM, Wilken GH, Macarthur H.
    Neurosci Lett; 2016 Jan 26; 612():178-184. PubMed ID: 26704434
    [Abstract] [Full Text] [Related]

  • 7. Molecular and neurochemical mechanisms in PD pathogenesis.
    Paris I, Lozano J, Perez-Pastene C, Muñoz P, Segura-Aguilar J.
    Neurotox Res; 2009 Oct 26; 16(3):271-9. PubMed ID: 19526278
    [Abstract] [Full Text] [Related]

  • 8. Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson's Disease.
    Segura-Aguilar J, Muñoz P, Paris I.
    Curr Med Chem; 2016 Oct 26; 23(4):346-59. PubMed ID: 26695514
    [Abstract] [Full Text] [Related]

  • 9. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
    Luo Z, Ahlers-Dannen KE, Spicer MM, Yang J, Alberico S, Stevens HE, Narayanan NS, Fisher RA.
    JCI Insight; 2019 May 23; 5(13):. PubMed ID: 31120439
    [Abstract] [Full Text] [Related]

  • 10. Impact of Dopamine Oxidation on Dopaminergic Neurodegeneration.
    Zhang S, Wang R, Wang G.
    ACS Chem Neurosci; 2019 Feb 20; 10(2):945-953. PubMed ID: 30592597
    [Abstract] [Full Text] [Related]

  • 11. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R, Cunha-Oliveira T, Rego AC.
    Free Radic Biol Med; 2013 Sep 20; 62():186-201. PubMed ID: 23743292
    [Abstract] [Full Text] [Related]

  • 12. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C, Bender A, García-Arumí E, Melià MJ, Bové J, Laub C, Klopstock T, Elstner M, Mounsey RB, Teismann P, Prolla T, Andreu AL, Vila M.
    Brain; 2013 Aug 20; 136(Pt 8):2369-78. PubMed ID: 23884809
    [Abstract] [Full Text] [Related]

  • 13. On the role of endogenous neurotoxins and neuroprotection in Parkinson's disease.
    Segura-Aguilar J.
    Neural Regen Res; 2017 Jun 20; 12(6):897-901. PubMed ID: 28761417
    [Abstract] [Full Text] [Related]

  • 14. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E, Santin MD, Valabrègue R, Mangone G, Gaurav R, Pyatigorskaya N, Hutchison M, Yahia-Cherif L, Villain N, Habert MO, Arnulf I, Leu-Semenescu S, Dodet P, Vila M, Corvol JC, Vidailhet M, Lehéricy S.
    Brain; 2021 Nov 29; 144(10):3114-3125. PubMed ID: 33978742
    [Abstract] [Full Text] [Related]

  • 15. RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.
    Ahlers-Dannen KE, Spicer MM, Fisher RA.
    Mol Pharmacol; 2020 Dec 29; 98(6):730-738. PubMed ID: 32015009
    [Abstract] [Full Text] [Related]

  • 16. Neuronal vulnerability in Parkinson's disease.
    Double KL.
    Parkinsonism Relat Disord; 2012 Jan 29; 18 Suppl 1():S52-4. PubMed ID: 22166454
    [Abstract] [Full Text] [Related]

  • 17. Dopamine oxidation and autophagy.
    Muñoz P, Huenchuguala S, Paris I, Segura-Aguilar J.
    Parkinsons Dis; 2012 Jan 29; 2012():920953. PubMed ID: 22966478
    [Abstract] [Full Text] [Related]

  • 18. Melanin and Neuromelanin: Linking Skin Pigmentation and Parkinson's Disease.
    Krainc T, Monje MHG, Kinsinger M, Bustos BI, Lubbe SJ.
    Mov Disord; 2023 Feb 29; 38(2):185-195. PubMed ID: 36350228
    [Abstract] [Full Text] [Related]

  • 19. Oxidation of dopamine to aminochrome as a mechanism for neurodegeneration of dopaminergic systems in Parkinson's disease. Possible neuroprotective role of DT-diaphorase.
    Graumann R, Paris I, Martinez-Alvarado P, Rumanque P, Perez-Pastene C, Cardenas SP, Marin P, Diaz-Grez F, Caviedes R, Caviedes P, Segura-Aguilar J.
    Pol J Pharmacol; 2002 Feb 29; 54(6):573-9. PubMed ID: 12866711
    [Abstract] [Full Text] [Related]

  • 20. A Preclinical Model for Parkinson's Disease Based on Transcriptional Gene Activation via KEAP1/NRF2 to Develop New Antioxidant Therapies.
    Segura-Aguilar J, Mannervik B.
    Antioxidants (Basel); 2023 Mar 09; 12(3):. PubMed ID: 36978921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.